BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 18086342)

  • 1. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
    Larson RA
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S13-20. PubMed ID: 18086342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel purine nucleoside analogues for hematological malignancies.
    Korycka A; Lech-Marańda E; Robak T
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):123-36. PubMed ID: 18537755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
    Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
    Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clofarabine and nelarabine: two new purine nucleoside analogs.
    Gandhi V; Plunkett W
    Curr Opin Oncol; 2006 Nov; 18(6):584-90. PubMed ID: 16988579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Older and new purine nucleoside analogs for patients with acute leukemias.
    Robak P; Robak T
    Cancer Treat Rev; 2013 Dec; 39(8):851-61. PubMed ID: 23566572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clofarabine (2-chloro-2'-fluoro-2'-deoxyarabinosyladenine)--biochemical aspects of anticancer activity.
    Majda K; Lubecka K; Kaufman-Szymczyk A; Fabianowska-Majewska K
    Acta Pol Pharm; 2011; 68(4):459-66. PubMed ID: 21796927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nelarabine: a novel purine antimetabolite antineoplastic agent.
    Buie LW; Epstein SS; Lindley CM
    Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clofarabine in pediatric acute leukemia: current findings and issues.
    Hijiya N; Barry E; Arceci RJ
    Pediatr Blood Cancer; 2012 Sep; 59(3):417-22. PubMed ID: 22354543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies.
    Furman RR; Hoelzer D
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S29-34. PubMed ID: 18086344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent.
    Gandhi V; Balakrishnan K
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S8-12. PubMed ID: 18086347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.
    Lech-Maranda E; Korycka A; Robak T
    Mini Rev Med Chem; 2009 Jun; 9(7):805-12. PubMed ID: 19519505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia.
    Steinherz PG; Meyers PA; Steinherz LJ; Jeha S
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):656-8. PubMed ID: 17805046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Kadia TM; Gandhi V
    Expert Rev Hematol; 2017 Jan; 10(1):1-8. PubMed ID: 27869523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and development of clofarabine: a nucleoside analogue for treating cancer.
    Bonate PL; Arthaud L; Cantrell WR; Stephenson K; Secrist JA; Weitman S
    Nat Rev Drug Discov; 2006 Oct; 5(10):855-63. PubMed ID: 17016426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
    Jeha S; Gaynon PS; Razzouk BI; Franklin J; Kadota R; Shen V; Luchtman-Jones L; Rytting M; Bomgaars LR; Rheingold S; Ritchey K; Albano E; Arceci RJ; Goldman S; Griffin T; Altman A; Gordon B; Steinherz L; Weitman S; Steinherz P
    J Clin Oncol; 2006 Apr; 24(12):1917-23. PubMed ID: 16622268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.
    Gandhi V; Kantarjian H; Faderl S; Bonate P; Du M; Ayres M; Rios MB; Keating MJ; Plunkett W
    Clin Cancer Res; 2003 Dec; 9(17):6335-42. PubMed ID: 14695132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
    Korycka A; Błoński JZ; Robak T
    Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
    Galmarini CM
    IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect?
    Gore L; Stelljes M; Quinones R
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S35-9. PubMed ID: 18086346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Justice R; Pazdur R
    Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.